Qarziba for Patients in Relapsed/Refractory High-grade Osteosarcoma

Summary

Limited progress has been made in identifying novel targets that may be therapeutic for Osteosarcoma(OS) and there remains an urgent need for the development of new agents that are effective in improving survival. From this perspective, repurposing already proven targets in other tumors may offer new opportunities for OS in children and young adults. Anecdotal evidence of anti-GD2 therapy exists in OS from prior Phase 1 trials that included patients with OS.

Timeline

Start

2023-11-30

Primary completion

2025-12-15

Completion

2026-12-15

Drugs

Indications